Peripheral T-Cell Lymphomas (PTCL) Emerging and Marketed Drugs, 2020

Peripheral T-Cell Lymphomas (PTCL) Emerging and Marketed Drugs, 2020

“DelveInsight”
Peripheral T-Cell Lymphomas (PTCL) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Peripheral T-Cell Lymphomas (PTCL) market. A detailed picture of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape is provided, which includes the disease overview and Peripheral T-Cell Lymphomas (PTCL) treatment guidelines.

Peripheral T-Cell Lymphoma (PTCL) is a diverse group of aggressive lymphomas that develop from mature T-cells and natural killer (NK) cells.

 

Scope of Peripheral T-Cell Lymphoma Report

  • The Peripheral T-Cell Lymphomas (PTCL) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Peripheral T-Cell Lymphomas (PTCL) across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Peripheral T-Cell Lymphomas (PTCL) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Peripheral T-Cell Lymphomas (PTCL) research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Peripheral T-Cell Lymphomas (PTCL) .

 

Request for sample pages

 

PTCL Emerging Drugs included in the report 

  1. Denileukin diftitox: Eisai
  2. SP-02 (Darinaparsin, ZIO-101): Solasia Pharma
  3. Fenretinide (4-HPR): CerRx
  4. Tipifarnib: Kura Oncology
  5. HBI-8000: HUYA Bioscience International/Quintiles, Inc.
  6. COPIKTRA (Duvelisib): Verastem
  7. Genolimzumab (GB226): Genor Biopharma
  8. Azacitidine (CC-486): Celgene Corporation
  9. Tislelizumab: BeiGene
  10. Lacutamab/IPH4102: Innate Pharma
  11. AFM13: Affimed GmbH
  12. Opdivo (nivolumab) + Cabiralizumab: Bristol-Myers Squibb
  13. Bavencio (avelumab): Pfizer
  14. Keytruda (pembrolizumab): Merck Sharp & Dohme Corp.
  15. STI-3031/IMC-001: Sorrento Therapeutics
  16. ALRN 6924: Aileron Therapeutics
  17. Masitinib: AB Science
  18. Ruxolitinib: Incyte Corporation/Novartis
  19. Aplidin (plitidepsin): PharmaMar
  20. ASTX660: Otsuka Pharmaceutical/Astex Pharmaceuticals

Table of contents

 

1. Report Introduction

2. Peripheral T-Cell Lymphomas (PTCL)  

2.1. Overview

2.2. History 

2.3. Peripheral T-Cell Lymphomas (PTCL) Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Peripheral T-Cell Lymphomas (PTCL) Diagnosis 

2.6.1. Diagnostic Guidelines

3. Peripheral T-Cell Lymphomas (PTCL)  Current Treatment Patterns

3.1. Peripheral T-Cell Lymphomas (PTCL) Treatment Guidelines

4. Peripheral T-Cell Lymphomas (PTCL)  – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Peripheral T-Cell Lymphomas (PTCL)  companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Peripheral T-Cell Lymphomas (PTCL)  Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Peripheral T-Cell Lymphomas (PTCL)  Acquisition Analysis

5. PTCL Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Peripheral T-Cell Lymphomas (PTCL) Late Stage Products (Phase-III)

7. Peripheral T-Cell Lymphomas (PTCL) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Peripheral T-Cell Lymphomas (PTCL) Discontinued Products

13. Peripheral T-Cell Lymphomas (PTCL)  Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition 

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report 

14. Peripheral T-Cell Lymphomas (PTCL)  Key Companies

15. Peripheral T-Cell Lymphomas (PTCL)  Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Peripheral T-Cell Lymphomas (PTCL)  Unmet Needs

18. Peripheral T-Cell Lymphomas (PTCL)  Future Perspectives

19. Peripheral T-Cell Lymphomas (PTCL)  Analyst Review  

20. Appendix

21. PTCL Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation 

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/